# Trending Content OS — Daily Run
**Run date:** 2026-10-01 | **Niche:** Health & Wellness

---

## 1. Preflight Summary

| Check | Status |
|---|---|
| All config sections present | ✅ true |
| `site_niche` / `target_audience` set | ✅ / ✅ |
| `site_url` set | ❌ not set — self-check skipped, competitor-list fallback used (configs/competitor_list.yaml) |
| SerpAPI connected | ✅ true |
| Google Trends available | ✅ true (`google_trends_tool: serpapi_prefetch`) |
| Google News Radar injected | ✅ true (144 unique headlines, 12 queries) |
| Reddit / social monitoring | ⚠️ inactive this run (not injected) |
| Content database | ❌ disabled — competitor fallback only |
| **Next action** | `run_signal_listener` → proceeded with full pipeline |

**Deferred topics check:** `data/deferred_topics.yaml` — no entries past `recheck_on` today.
**Run-history check:** No single theme has recurred in 3+ consecutive runs; recall-cluster volume (FDA actions) has been elevated for 4 straight days — flagged below as a recurring pattern to watch, not a staleness problem (each recall is a genuinely distinct product).

---

## 2. Google News Radar Coverage Summary

Six main clusters identified across the 144-headline radar:

| Cluster | Examples | Disposition |
|---|---|---|
| **Healthcare policy / business / insurance** | [Healthcare Dive](https://www.healthcaredive.com/news/insurers-say-ai-could-add-billions-in-health-costs-billing-companies-disag/831497/), [PBS](https://www.pbs.org/newshour/show/health-care-costs-a-major-concern-for-voters-ahead-of-midterms), [MPR News](https://www.mprnews.org/story/2026/09/29/healthpartners-and-essentia-health-announce-plan-to-merge), [DOJ](https://www.justice.gov/opa/pr/texas-mental-health-clinic-owner-convicted-26m-scheme-defraud-military-health-benefits) | **Rejected** — off-category (pure business/political/legal, no patient-health evidence angle) |
| **Community wellness fairs & celebrity wellness** | [People.com — Julianne Hough](https://people.com/julianne-hough-talks-beauty-wellness-dancing-with-the-stars-exclusive-12148999), CDCR, Marquette, UAMS, Fredonia, Inter Miami, Santa Barbara, KCRA, Buffalo Bills wellness fairs | **Rejected** — excluded categories (local hospital/community news, celebrity wellness without evidence) |
| **Medical study / research** | [Stanford lymphedema drug](https://med.stanford.edu/news/all-news/2026/09/lymphedema-drug.html), [insomnia–stroke study](https://www.news-medical.net/news/20260928/Study-links-insomnia-to-higher-stroke-and-hospitalization-risks.aspx), [Nature reproducibility](https://www.nature.com/articles/s41591-026-04667-1), [Apyx Medical](https://www.globenewswire.com/news-release/2026/09/29/3370752/0/en/apyx-medical-announces-new-clinical-study-demonstrating-renuvion-s-impact-on-skin-quality.html) | **Mixed** — lymphedema study **retained** (02b pass); insomnia-stroke study **rejected** (02b — unverifiable primary source); reproducibility/Apyx **rejected** (low audience fit / marketing) |
| **Clinical trial modernization** | [HHS SURPASS](https://www.hhs.gov/press-room/hhs-arpa-h-launch-surpass-modernize-clinical-trials.html), [STAT](https://www.statnews.com/2026/09/30/hhs-arpa-h-clinical-trials-artificial-intelligence-surpass-program/), [Axios](https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign), [BioPharma Dive](https://www.biopharmadive.com/news/hhs-clinical-trial-speed-arpa-h-drug-testing/831909/), [KUT](https://www.kut.org/health/2026-10-01/austin-tx-rfk-jr-hhs-clinical-trials-ut-dell-medical-school) | **Retained — P1** (multi-source convergence, tier-1 + tier-2 sourcing) |
| **FDA recalls** (chlorthalidone BP meds, thyroid tablets, sugar) | [EatingWell](https://www.eatingwell.com/sugar-recall-sept-2026-12146967), [The Hill](https://thehill.com/homenews/6115677-blood-pressure-medication-recalled-nationwide-under-fdas-class-ii-risk-level/), [USA Today](https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/09/24/thyroid-tablet-medicine-recall-fda/91916444007/) | **Rejected — existing/duplicate.** All three already covered 9/24–9/30; no new development (no case counts, no new class upgrade) since prior coverage |
| **Long COVID / clinical trial results** | [NIH antiviral trial](https://www.nih.gov/news-events/nih-research-matters/antiviral-drug-did-not-improve-long-covid-symptoms), [St. Louis American — Black patients barriers](https://www.stlamerican.com/your-health-matters/black-patients-face-barriers-to-clinical-trials/) | **Monitored (NIH trial, P5)** / **Rejected** (Black-patients-barriers story duplicates 9/24 coverage, no new data) |

**Google Trends cross-check:** No credible news corroboration found for several rising Trends queries (`sean o'mara diet`, `neko health`, `purple yam`, `health insurance giant`) — treated as autocomplete/social noise, rejected as weak signal per Skill 01 Step 2.4.

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: "2026-10-01T00:00:00Z"
  run_completed_at: "2026-10-01T00:00:00Z"
  total_signals_reviewed: 150
  total_signals_retained: 3
  total_rejected: 147
  google_trends_available: true
  search_velocity_source: "google_trends"
  rejection_breakdown:
    off_category: 24
    brand_safety: 0
    duplicate: 9
    weak_signal: 6
    unverified_claim: 1
    other: 107   # radar items not individually itemized (sub-clusters of rejected groups above)
  highest_priority_topic: "HHS/ARPA-H SURPASS clinical trial modernization program"
  strongest_signal_source: "HHS.gov + STAT News + Axios + BioPharma Dive (multi-source convergence)"
  tools_unavailable: ["reddit_api", "social_search (X/Twitter)"]
  notes: >
    Google News Radar's FDA-recall cluster (chlorthalidone, thyroid, sugar) is high-volume
    but fully duplicative of the last 7 days' coverage — judgment call to suppress rather than
    re-surface, since no new casualty/class/dosage development was found. Wellness-fair/celebrity
    cluster (11 items) rejected as a block per category_rules. Trends-only candidates without
    news corroboration (sean o'mara diet, neko health, purple yam) held to weak-signal standard.
```

---

## 4. Skill 02b — Health Claim Verification Gate: Routing Summary

```yaml
- topic: "Stanford Medicine lymphedema drug study"
  risk_type: drug_or_treatment_claim
  gate_result: pass
  primary_source_found: true
  primary_source_type: trusted_secondary   # Stanford's own institutional research news
  claim_alignment: matches
  confidence_cap: medium
  notes: "Single-source institutional release from the research institution itself. Stanford
    Medicine is tier-1, but DOI/journal link not independently confirmed — verify before publishing."
  recommended_next_skill: 03_entity_expander

- topic: "NIH — antiviral drug did not improve Long COVID symptoms"
  risk_type: clinical_trial
  gate_result: pass
  primary_source_found: true
  primary_source_type: clinical_trial_record   # NIH.gov direct institutional reporting
  claim_alignment: matches
  confidence_cap: null
  notes: "NIH.gov is the primary institutional source; claim is a straightforward negative trial
    result, no overstatement detected. Passed to scoring — did not clear trend_strength threshold."
  recommended_next_skill: 03_entity_expander

- topic: "Insomnia linked to higher stroke and hospitalization risk"
  risk_type: study_or_research
  gate_result: reject
  primary_source_found: false
  primary_source_type: none
  claim_alignment: unknown
  confidence_cap: null
  notes: "Single secondary outlet (News-Medical, not in trusted_sources.yaml), no journal/DOI/
    researcher identified at headline level. No corroborating outlet found in radar."
  rejection_reason: unverifiable_health_claim
  recommended_next_skill: 12_editorial_priority_board   # exits to rejected log
```

---

## 5. Final Editorial Priority Board

| # | Priority | Topic | Trend | Opp | Discover | Urgency | Confidence |
|---|---|---|---|---|---|---|---|
| 1 | **P1** | HHS/ARPA-H SURPASS clinical trial modernization | 82 | 82 | 4 | today | high |
| 2 | **P3** | Stanford lymphedema drug study | 58 | 79 | 4 | this_week | low |
| 3 | **P5 (Monitor)** | NIH Long COVID antiviral trial (negative result) | 45 | 74 | 3 | this_week | low |

```yaml
priority_board:
  - topic: "HHS and ARPA-H launch SURPASS program to accelerate clinical trials with AI"
    priority_level: P1
    publish_timing: immediate
    primary_entity: "HHS / ARPA-H SURPASS Program"
    signal_type: policy_or_regulatory_change
    allowed_category: "medical research and clinical trials"
    trend_strength_score: 82
    opportunity_score: 82
    discover_score: 4
    urgency: today
    confidence: high
    content_status: new
    source_count: 8
    recommended_angle: "What SURPASS actually changes for patients trying to access a clinical trial — not the policy press release, the practical access story"
    why_now: "HHS/ARPA-H announced 9/30; STAT, Axios, BioPharma Dive, and KUT (RFK Jr./Dell Medical School partnership) all filed same-day/next-day coverage — a live, converging national story with no consumer-facing explainer yet"
    primary_headline: "HHS Just Launched a Program to Speed Up Clinical Trials — Here's What That Means If You're Trying to Get Into One"
    next_steps: "Assign P1 writer today; full brief below; verify SURPASS program scope against HHS.gov primary notice before publishing"
    notes: "Strongest story of the run — tier-1 primary source (HHS.gov) plus 7 corroborating outlets across news/trade/local. Also ties into a previously-covered thread (clinical trial access for Black and pregnant patients, 9/24) — consider internal link."

  - topic: "Stanford Medicine study shows promise for a new lymphedema drug"
    priority_level: P3
    publish_timing: scheduled
    primary_entity: "Stanford Medicine lymphedema drug trial"
    signal_type: study_or_research
    allowed_category: "chronic disease management"
    trend_strength_score: 58
    opportunity_score: 79
    discover_score: 4
    urgency: this_week
    confidence: low
    content_status: new
    source_count: 1
    recommended_angle: "What this drug does differently than existing lymphedema management options — and how far it is from patient availability"
    why_now: "Stanford Medicine published 9/30; no other outlet has picked it up yet — early-mover opportunity on a thin SERP, but single-source risk"
    primary_headline: "A New Drug Is Showing Promise for Lymphedema — Here's What the Research Actually Shows"
    next_steps: "Confirm DOI/journal citation from Stanford release before assigning; hold for 48h to see if wire pickup corroborates"
    notes: "⚠️ Single institutional source — verify trial phase and DOI before publishing. Passed Skill 02b with medium-confidence cap on primary sourcing."

  - topic: "NIH-funded trial: antiviral drug did not improve Long COVID symptoms"
    priority_level: P5
    publish_timing: monitor
    primary_entity: "NIH Long COVID antiviral trial"
    signal_type: clinical_trial
    allowed_category: "infectious disease"
    trend_strength_score: 45
    opportunity_score: 74
    discover_score: 3
    urgency: this_week
    confidence: low
    content_status: new
    source_count: 1
    recommended_angle: "N/A — monitor only"
    why_now: "NIH.gov posted 9/29; no other outlet has corroborated. Trend strength below the 50-point pass threshold on single-source basis."
    primary_headline: "N/A — monitor only"
    next_steps: "Recheck in 3 days for wire pickup; promote to full brief only if a second outlet corroborates or framing crystallizes around 'what Long COVID patients should try instead'"
    notes: "Passed 02b (primary source is NIH.gov itself) but held at Trend Scorer stage — single-source, no news-cycle convergence yet."

summary:
  total_topics: 3
  high_priority_count: 1
  immediate_actions: "Assign HHS SURPASS clinical trial story today (P1); hold Stanford lymphedema for DOI verification before writing"
```

---

## 6. Editorial Briefs

### Brief 1 (P1 — Full Deep-Dive): HHS SURPASS Clinical Trial Modernization

```yaml
brief:
  primary_headline: "HHS Just Launched a Program to Speed Up Clinical Trials — Here's What That Means If You're Trying to Get Into One"
  alternate_headlines:
    - "The Government's New Plan to Fix Clinical Trials, Explained"
    - "Why Clinical Trials Take So Long — and What's Changing in 2026"
    - "AI Is About to Change How You Get Matched to a Clinical Trial"
  topic: "HHS and ARPA-H launch SURPASS program to accelerate clinical trials with AI"
  primary_entity: "HHS / ARPA-H SURPASS Program"
  search_intent: "informational + practical (how-to find/access a trial)"
  angle: "Translate a federal policy announcement into a patient-access story: what SURPASS changes about trial timelines, AI-matching, and enrollment barriers — grounded in the NYT's own recent reporting on why cancer trials take so long, and the structural exclusion issues raised in the 9/24 clinical-trial-diversity story."
  why_now: "HHS/ARPA-H announcement (9/30) converged same-day/next-day across STAT, Axios, BioPharma Dive, Fierce Biotech, and local coverage (KUT — RFK Jr./Dell Medical School partnership); no outlet has yet written the consumer-facing 'what this means for you' explainer."
  integrity_flags:
    - "⚠️ Integrity note: This is a program launch, not a completed outcome — avoid implying trials will immediately speed up; frame as an initiative with a stated goal."
    - "⚠️ Integrity note: Note political context (RFK Jr./HHS framing vs. Chinese biotech competition per BioPharma Dive) without editorializing — stick to patient-access facts."
  outline:
    intro: "A federal program most patients have never heard of could change how fast you get into a clinical trial."
    sections:
      - "What SURPASS actually is (HHS/ARPA-H's stated goals)"
      - "Why clinical trials are currently so slow (tie to NYT op-ed + Nature capacity piece)"
      - "How AI-matching is supposed to help (Pfizer's parallel effort as real-world example)"
      - "What this doesn't fix yet — exclusion of Black patients and pregnant/lactating people (link to 9/24 coverage)"
      - "How to actually find and enroll in a trial today (ClinicalTrials.gov)"
    conclusion: "What to watch for as SURPASS rolls out"
  key_data_points:
    - "HHS/ARPA-H official program launch, 9/30/2026"
    - "Canadian $5M accelerated trial program cut trial start-up to 45 days (comparative benchmark)"
  source_plan:
    - { publisher: "HHS.gov", url: "https://www.hhs.gov/press-room/hhs-arpa-h-launch-surpass-modernize-clinical-trials.html", tier: 1, used_for: "Primary announcement" }
    - { publisher: "STAT News", url: "https://www.statnews.com/2026/09/30/hhs-arpa-h-clinical-trials-artificial-intelligence-surpass-program/", tier: 1, used_for: "Program detail + context" }
    - { publisher: "Axios", url: "https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign", tier: 2, used_for: "Policy framing" }
    - { publisher: "BioPharma Dive", url: "https://www.biopharmadive.com/news/hhs-clinical-trial-speed-arpa-h-drug-testing/831909/", tier: 2, used_for: "Industry/competitive context" }
    - { publisher: "KUT", url: "https://www.kut.org/health/2026-10-01/austin-tx-rfk-jr-hhs-clinical-trials-ut-dell-medical-school", tier: 2, used_for: "Regional implementation example" }
    - { publisher: "ClinicalTrials.gov", url: "https://clinicaltrials.gov", tier: 1, used_for: "Patient how-to-enroll resource" }
  evidence_requirements: "Moderate — primary government source is sufficient; no peer-reviewed study required since this is a program/policy story"
  expert_sources:
    - { type: "Clinical researcher / principal investigator", name: "Cite from STAT/Axios coverage", reason: "Credibility on what 'faster trials' means in practice" }
  internal_links: ["Clinical trials still exclude Black patients and pregnant/lactating people (9/24 coverage)"]
  visual_brief: "Hero: simple explainer graphic of trial timeline before/after; avoid stock photos of generic 'lab coat' imagery"
  seo:
    primary_keyword: "clinical trial access 2026"
    supporting_keywords: ["SURPASS program HHS", "how to find a clinical trial", "AI clinical trial matching"]
    format: "explainer + FAQ"
    schema_markup: "Article + FAQPage"
    cluster: "medical research and clinical trials"
  discover_notes: "High entity clarity (SURPASS/HHS/ARPA-H) + natural AI query fit ('what is the SURPASS program') + primary source density + clear SERP gap on consumer framing"
  key_takeaways:
    - "HHS/ARPA-H launched SURPASS to cut clinical trial start-up and enrollment time"
    - "AI-matching is a core piece of the plan, mirroring private-sector efforts like Pfizer's"
    - "Structural access barriers (race, pregnancy status) aren't directly addressed by this program"
  estimated_word_count: "1,100-1,300"
execution_notes: "Hold for HHS.gov primary notice confirmation on exact program scope before filing"
confidence: high
pass_to_next_layer: true
recommended_next_skill: 11_discover_optimizer
```

### Brief 2 (P3 — Concise): Stanford Lymphedema Drug Study

```yaml
brief:
  headline: "A New Drug Is Showing Promise for Lymphedema — Here's What the Research Actually Shows"
  topic: "Stanford Medicine study shows promise for a new lymphedema drug"
  angle: "Explain what the drug targets and how far it is from patient availability, grounded strictly in Stanford's own study language rather than overstating 'breakthrough' framing."
  key_data_points:
    - "Stanford Medicine-led research findings published 9/30/2026"
  integrity_flags:
    - "⚠️ Integrity note: Single-source story — verify trial phase (preclinical vs. human trial) and DOI/journal citation before publishing; do not imply near-term availability."
  expert_type_needed: "Oncologist or lymphedema specialist to contextualize current standard of care"
  seo:
    primary_keyword: "new lymphedema drug"
    format: "news explainer"
    serp_difficulty: "Easy"
  sources:
    - { publisher: "Stanford Medicine", url: "https://med.stanford.edu/news/all-news/2026/09/lymphedema-drug.html" }
  estimated_word_count: "500-700"
```

---

## 7. Rejected Topics Log

| Topic | Reason |
|---|---|
| FDA chlorthalidone blood pressure medication recall | `existing` — duplicate of 9/28, 9/29 coverage; no new development |
| FDA thyroid tablet (Vitruvias) Class I recall | `existing` — duplicate of 9/24 coverage |
| FDA sugar contamination recall | `existing` — duplicate of 9/30 coverage |
| Clinical trials exclude Black patients (St. Louis American) | `existing` — duplicate of 9/24 coverage, no new data cited |
| Stanford UPF school menu follow-up | `existing` — duplicate of 9/29 coverage, no new development |
| HealthPartners/Essentia Health merger | `off_category` — business/regional merger, low patient-health evidence angle |
| Texas mental health clinic fraud conviction (DOJ) | `off_category` — legal/fraud news, not health content |
| Healthcare costs & midterm voters (PBS) | `off_category` — pure political healthcare opinion |
| Community wellness fairs (CDCR, Marquette, UAMS, Fredonia, Champaign, Inter Miami, Santa Barbara, KCRA, Buffalo Bills, American Legion, Lutheran Church) | `off_category` — excluded (local hospital/community news) |
| Julianne Hough beauty & wellness interview | `off_category` — excluded (celebrity wellness without evidence) |
| Apyx Medical clinical study (Renuvion) | `off_category` — product marketing / press release |
| Nature "Reproducibility in biomedical research" | `other` — low audience fit, too academic/methodological for general audience |
| Insomnia linked to stroke/hospitalization risk | `unverified_claim` — rejected at Skill 02b, no traceable primary source |
| "Sean O'Mara diet" trending query | `weak_signal` — Trends-only, no news corroboration |
| "neko health" / "purple yam" / "health insurance giant" trending queries | `weak_signal` — autocomplete noise, no credible corroboration |

---

## 8. Integrity Flags (Consolidated)

- ⚠️ **HHS SURPASS**: Frame as a program *launch*, not a completed outcome — avoid implying trials are already faster.
- ⚠️ **HHS SURPASS**: Avoid editorializing on political framing (RFK Jr./China-competition angle in BioPharma Dive); stick to patient-access facts.
- ⚠️ **Stanford lymphedema drug**: Single-source story — confirm trial phase and DOI before publishing; do not imply near-term patient availability.

---

## 9. Run Notes

- `site_url` not configured — self-check skipped; competitor-list fallback (configs/competitor_list.yaml) used to inform SERP-gap judgment instead.
- Reddit and X/social collectors were not available this run; no social-only candidates were in play, so this did not materially affect retained picks.
- FDA recall volume remains elevated for a 5th consecutive day (chlorthalidone, thyroid, sugar, plus 9/25 meat/jalapeño/glutathione recalls) — worth a standing explainer piece ("Why are there so many FDA recalls right now?") as an evergreen P4 candidate in a future run, rather than continuing to individually re-surface duplicate recall stories.
- Recommend revisiting the NIH Long COVID antiviral trial (P5/Monitor) in 2–3 days for wire corroboration.
- Dashboard not generated as a live HTML file in this environment; structured output above is the complete, publishable equivalent per the requested report sections.